MannKind Corp
MNKD
₹332.65
Share price
-3.54%
Change (1 day)
-31.75%
Change (1 year)
Categories
Revenue for MannKind Corp (MNKD)
Revenue in 2025 (TTM): ₹25.19 Billion
According to MannKind Corp's latest financial reports the company's current revenue (TTM 
) is ₹25.91 Billion. In 2024 the company made a revenue of ₹24.49 Billion an increase over the revenue in the year 2023 that were of ₹16.56 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MannKind Corp from 2009 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | ₹25.19 B | 2.86% |
| 2024 | ₹24.49 B | 47.87% |
| 2023 | ₹16.56 B | 100.62% |
| 2022 | ₹8.25 B | 47.03% |
| 2021 | ₹5.61 B | 17.86% |
| 2020 | ₹4.76 B | 5.98% |
| 2019 | ₹4.49 B | 130.77% |
| 2018 | ₹1.94 B | 159.75% |
| 2017 | ₹0.74 B | -93.69% |
| 2016 | ₹11.87 B | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | -100% |
| 2012 | ₹1.91 M | -27.55% |
| 2011 | ₹2.64 M | -36.53% |
| 2010 | ₹4.16 M | |
| 2009 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Halozyme Therapeutics HALO | ₹94.42 B | 264.36% | 🇺🇸 USA |
 Novo Nordisk NVO | ₹3.808 T | 14,594.59% | 🇩🇰 Denmark |
 Merck MRK | ₹5.566 T | 21,379.53% | 🇺🇸 USA |
 Eli Lilly LLY | ₹4.267 T | 16,366.41% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | ₹7.59 B | -70.68% | 🇺🇸 USA |
 Pfizer PFE | ₹5.439 T | 20,889.26% | 🇺🇸 USA |